ArticleCancer medicine2023

Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.

G Martini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.